Literature DB >> 19077112

Tissue factor and heart inflammation.

R Pawlinski1, N Mackman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19077112      PMCID: PMC2834286          DOI: 10.1111/j.1538-7836.2008.03257.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  21 in total

Review 1.  The cardiovascular actions of protease-activated receptors.

Authors:  Susan F Steinberg
Journal:  Mol Pharmacol       Date:  2004-09-15       Impact factor: 4.436

Review 2.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

Review 3.  Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction.

Authors:  Kai Zacharowski; Paula Zacharowski; Sonja Reingruber; Peter Petzelbauer
Journal:  J Mol Med (Berl)       Date:  2006-05-06       Impact factor: 4.599

4.  The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury.

Authors:  Peter Petzelbauer; Paula A Zacharowski; Yasuhiro Miyazaki; Peter Friedl; Georg Wickenhauser; Francis J Castellino; Marion Gröger; Klaus Wolff; Kai Zacharowski
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

5.  Human peripheral blood monocytes express protease receptor-2 and respond to receptor activation by production of IL-6, IL-8, and IL-1{beta}.

Authors:  Ulrika Johansson; Charlotte Lawson; Michael Dabare; Denise Syndercombe-Court; Adrian C Newland; Gareth L Howells; Marion G Macey
Journal:  J Leukoc Biol       Date:  2005-07-06       Impact factor: 4.962

6.  Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection.

Authors:  Farshid Noorbakhsh; Nathalie Vergnolle; Justin C McArthur; Claudia Silva; Mohammed Vodjgani; Patricia Andrade-Gordon; Morley D Hollenberg; Christopher Power
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

7.  Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in mice.

Authors:  L A Snyder; K A Rudnick; R Tawadros; A Volk; S H Tam; G M Anderson; P J Bugelski; J Yang
Journal:  J Thromb Haemost       Date:  2007-11-14       Impact factor: 5.824

8.  Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy.

Authors:  Rafal Pawlinski; Michael Tencati; Craig R Hampton; Tetsuro Shishido; Tara A Bullard; Liam M Casey; Patricia Andrade-Gordon; Matthias Kotzsch; Denise Spring; Thomas Luther; Jun-ichi Abe; Timothy H Pohlman; Edward D Verrier; Burns C Blaxall; Nigel Mackman
Journal:  Circulation       Date:  2007-10-29       Impact factor: 29.690

9.  Role of cardiac myocyte tissue factor in heart hemostasis.

Authors:  R Pawlinski; M Tencati; T Holscher; B Pedersen; T Voet; R E Tilley; P Marynen; N Mackman
Journal:  J Thromb Haemost       Date:  2007-08       Impact factor: 5.824

10.  SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts.

Authors:  Jennifer L Strande; Anna Hsu; Jidong Su; Xiangping Fu; Garrett J Gross; John E Baker
Journal:  Basic Res Cardiol       Date:  2007-04-30       Impact factor: 17.165

View more
  3 in total

1.  Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane A2 as a new player.

Authors:  Michael Bode; Nigel Mackman
Journal:  Vascul Pharmacol       Date:  2014-05-21       Impact factor: 5.773

Review 2.  Protease-activated receptors and myocardial infarction.

Authors:  Silvio Antoniak; Rafal Pawlinski; Nigel Mackman
Journal:  IUBMB Life       Date:  2011-03-24       Impact factor: 3.885

3.  A network study of chinese medicine xuesaitong injection to elucidate a complex mode of action with multicompound, multitarget, and multipathway.

Authors:  Linli Wang; Zheng Li; Xiaoping Zhao; Wei Liu; Yufeng Liu; Jihong Yang; Xiang Li; Xiaohui Fan; Yiyu Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-24       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.